Nextcure and collaborators provide clinical and research updates on nc318 and nc410 candidates at society for immunotherapy of cancer annual meeting

Beltsville, md., nov. 13, 2021 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced new data from two clinical studies and one research study presented at the society for immunotherapy of cancer (sitc) annual meeting in washington, d.c., and on a virtual platform. the data come from clinical studies evaluating nc318, a siglec-15 (s15) antibody, and nc410, a fusion protein of lair-2, in patients with advanced/metastatic solid tumors, as well as from a research study evaluating nc410's impact on t cell activation and myeloid cell polarization conducted in collaboration with the national cancer institute at the national institutes of health.
NXTC Ratings Summary
NXTC Quant Ranking